Product Information
TEGRETOL XR 200 MG TABLET is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $3.2473 per EA under NDC 00078051105. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Mar 25, 1996. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the carbamazepine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
200 mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078051105
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBAMAZEPINEApproval Type
New Drug (NDA)
FDA Application
NDA020234FDA Approved
3/25/1996
TE Code
AB
On Market Since
3/25/1996
Pharmacological Classes
Price Statistics
The NADAC for TEGRETOL XR 200 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 148.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.2473 per EA |
|---|---|
| All-time high | $3.2503 (May 13, 2026) |
| All-time low | $1.2843 (Dec 18, 2013) |
| 52-week high | $3.2503 |
| 52-week low | $3.1557 |
| Median price | $2.5895 |
| Average price | $2.5104 |
| Largest weekly change | +14.9% (Jan 15, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 88% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
carbamazepine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Mood Stabilizer class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TEGRETOL XR 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TEGRETOL XR 200 MG TABLET, manufactured by Novartis Pharmaceuticals Corporation, is $3.2473 per EA (NDC 00078051105), effective Sep 30, 2026.
How has the price of TEGRETOL XR 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for TEGRETOL XR 200 MG TABLET has risen 148.9%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TEGRETOL XR 200 MG TABLET?
Since Nov 28, 2013, the NADAC for TEGRETOL XR 200 MG TABLET has ranged from a low of $1.2843 (Dec 18, 2013) to a high of $3.2503 (May 13, 2026), with a median of $2.5895 per EA.
Are there cheaper alternatives to TEGRETOL XR 200 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBAMAZEPINE ER 200 MG TABLET, is $0.3989 per EA — about 88% below TEGRETOL XR 200 MG TABLET.
Who manufactures TEGRETOL XR 200 MG TABLET?
TEGRETOL XR 200 MG TABLET (NDC 00078051105) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.